Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

MedX to Present at Benzinga Healthcare Conference on September 30th

V.MDX

Mississauga, Ontario--(Newsfile Corp. - September 29, 2021) - MedX Health Corp. (TSXV: MDX) ("MedX" or the "Company"), a global leader in teledermatology, is pleased to announce its participation in the Benzinga Healthcare Small Cap Conference (the "Conference"), taking place virtually on Thursday, September 30th at 4:40 PM ET.

MedX President & CEO, Sylvain Desjeans, along with Mike Druhan, President Dermatological Services, will present the Company's vision for scaling access to its unique dermatological image capture technology and fully integrated telemedicine platform, DermSecure®. The screening platform features high-resolution image capture technology that enables the accurate evaluation of moles, lesions and other skin conditions, providing a complete, virtual dermatological assessment by a certified dermatologist within just 72 hours. Investors are invited to participate in an open Q&A session following the presentation.

An archived webcast will be made available for attendees who are not able to join the event live.

To attend the event, please register here.

About MedX

MedX is a leading medical device and software company focused on skin health. MedX's SIAscopy technology and DermSecure telemedicine platform consists of hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain-free, non-invasive manner, and software that creates real-time images for physicians and dermatologists to accurately evaluate all types of moles, lesions and other skin conditions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. Visit https://medxhealth.com.

Contact Information
Bill Mitoulas
MedX Health Corp.
bill@medxhealth.com
416-479-9547

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/98078

Tags:


USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse